Lou Gehrig Disease Report Is there a link between Lipitor and ALS?

Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease in the US, Maladie de Charcot in France and Motor Neuron Disease (MND) in the UK is a progressive neuromuscular disease characterised by the progressive degeneration of motor nerve cell in the brain (upper motor neurons) and spinal cord (lower motor). To date there is no cure for ALS. Present day medical management of the disease through the combinatorial use of medications and advancements in state-of-art technological devices for nutrition and breathing, have markedly increased the survival rate of ALS sufferers.

An article in SpokesmanReview states there may be a link between statins and ALS, with suggestions that Lipitor has triggered it in certain cases. The article cites the WHO as pointing out that high numbers have developed Lou Gehrig disease while on statins and advises doctors to discontinue therapy if patients develop ‘serious neuromuscular disease such as ALS like symptoms’. Could Lipitor (still the biggest selling drug) actually cause ALS while the company itself thinks it will aid in the treatment of MS?

The report examines key ALS/ Lou Gehrig markets such as:

- US

- Japan

- Germany

- France

- Italy

- Spain

- UK

Sanofi-Aventis' Rilutek (riluzole) is the only prescription drug currently approved for the treatment of ALS. Rilutek generated global revenue of over $153 million in 2006. Visiongain reveals that, Rilutek’s market value will continue to expand with, global revenues anticipated to exceed $129 million 2007 in the seven major markets across the globe. What will it be in 2012? This report tells you.

Visiongain’s ALS Market Analysis & Forecasts, delves into Rilutek’s monopoly over the market in recent years, it present market share and trends envisaged in the medium future. This current report presents a three hundred and sixty degree examination of how present changes in Governmental Pharmaceutical Policies will impact on Rilutek as the main treatment for ALS in the seven major markets. Plus we examine how current and new drug treatments can take hold of the market, plus which companies will succeed in each market.

The report provides in-depth market analysis upon these areas, and extensively identifies the challenges faced by new market entrants, and what exciting market opportunities exist in this therapeutic area.

Why You Must Buy This Report:

This report features tables, graphs and charts, news, insights, the past and present developments in ALS research. This report, will provide you with the complete understanding of the market indications for ALS, the institutions heralding ALS research, companies on the outlook to join in decoding, such matters as- directions to meeting primary unmet needs in ALS. When you buy this report, you will discover why big players in the biopharmaceutical business are filling their portfolios with niche medical devices and diagnostics technologies products through major M&A.

With unmet medical needs this market is set to grow with an ageing population and by how much? This report will tell you. Brought together in one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global ALS pharmaceutical market.

Key questions that this report answers are:

* What research over the past 20 years has failed and why?

* What R&D opportunities exist for ‘new comers’?

* Which current or future therapies will drive the ALS market?

* The key companies involved in the market and their analysis?

* What companies are joining in ALS research?

* What treatment besides Rilutek, can improve ALS survival rate?

* Which of the major markets has the highest prevalence?

* What is the present state of the disease awareness?

* Who are market leaders in medical devices M&A activities?

* Which emerging markets are forcing big pharma into M&A deals?

Unique benefits to you when you order this report:

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Publication Date: 02/08/07

Pages: 90

PDF Format
Table of Contents

Price
Single User Licence $2998.00
Department Licence 5 Users $5,998.00
Company-wide Intranet Licence $9,998.00